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Abstract
Now into his twenty-fourth year working in the pharmaceutical industry, the author shares twentyfour select things learned and experienced over that time. In this paper the author contextualises
these observations, interpretations, lessons, anecdotes and advice to provide general insights into
various aspects of technology transfer for a biopharmaceutical drug substance (active
pharmaceutical ingredient).

1. Never compromise on quality, and be audit-ready at all times
Audits are always quite intimidating, regardless of how well experienced you are. Be audit
ready at all times. Treat every decision as being potentially auditable by the regulatory
authorities. The key to audit readiness is practice, practice, practice! Therefore, from the very
start of the technology transfer project have a healthy degree of scepticism in all your
decisions, as if you were constantly defended a scientific hypothesis or submitting a paper for
publication. Be constantly thinking on and practicing the robustness of your scientific
justifications. When the time comes around for the audit you should be by now well versed
and fluent in your defence, enabling you to present with great confidence to the auditors.
Never compromise on quality. To avoid those costly remediation projects be audit ready in
everything you do, in every task completed, and every report written. A good scientific
argument will always win out in the end, Once the underlying data is dependable and
uncompromised (data integrity).
2. Take a right first-time approach and avoid remediation projects
Take a right first-time approach every time and beware those inevitable decisions designed
to move the project forward but at the obvious expense of GMP. This will always come back
around to haunt you in the end, and by then you will be on your own as most of the project
personnel responsible for the questionable decisions have now finished their contracts and
have already left the site. Inevitably you will then be involved in expensive and demoralising
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remediation projects, with the usual repercussions and recriminations, in order to try and fix
that which is broken to any substantial degree of satisfaction.
3. We are all part of the technology transfer project
One way or another, all project personnel who are onsite, employed and contracted as part
of a new build, are part of the greater technology transfer endeavour. Technology transfer
encompasses many aspects, including:
(a) design, implementation and commissioning and qualification (C&Q) of the process
equipment, utilities, facility and warehouse,
(b) design and installation, and qualification of the laboratories;
(c) preparation and implementation of the quality management system (QMS),
(d) preparation of batch and quality control (QC) documentation,
(e) operational and maintenance procedures,
(f) managing the process transfer,
(g) managing analytical method transfer,
(h) personnel training,
(i) supply chain management and material controls,
(j) process validation,
(k) additional process development studies,
(l) comparability studies,
(m) stability studies,
(n) preparation and submission of the manufacturing licensing application to the regulatory
authorities, and
(o) inspection readiness.
A visualisation of the many interrelationships amongst key tasks and activities is illustrated in
Figure-1, for a typical biopharmaceutical drug substance technology transfer project. There
are opportunities in abundance when you are part of a technology transfer project. Seize
upon each and every opportunity to learn and to grow professionally.
4. Be accountable, perform well, and offer good value
Every document generated and every task completed with your contributions is a valuable
company asset. All project personnel, be they either staff or contractors, must take it upon
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themselves to provide value for the services they provide. Do not be found wanting. Allow
yourself to be held accountable for the tasks you perform, individually or collectively. Compete
with yourself rather than against others. At the end of the project, for your own professional and
personal satisfaction, you need to be able to reconcile your hours and cost against those services
you provided, and be able to quantify the value and performance of those.

5. Knowledge sharing
Knowledge is powerful, but only when it is widely shared and liberally distributed. Hoarding
knowledge in the interest of power will disenfranchise both the hoarder and the rest of the
project team. Carefully manage and counsel those project personnel who tend towards
hoarding knowledge, before the inevitable schedule slippages occur and major project
milestones are missed. Team work is key.

6. Personnel training
A significant number of contractor personnel are generally required throughout the project
phase. For key personnel we must document and demonstrate competence and proficiencies.
Carefully customise efficient and effective training curricula for contract personnel. Excessive
allocation of extraneous training programs to key contract personnel can quickly absorb much
of their limited availability. This can often can lead to the necessity for extended contracts,
resulting in higher costs and schedule overruns.

7. Staff retention
No one is irreplaceable, but equally no one is readily expendable either, and there are many
challenges currently being faced by pharmaceutical organisations globally in the recruitment
and retention of talent. Projects are tough environments to be successful and thrive within,
with many highly capable people struggling, and reporting stress, feelings of anxiety, fatigue
and/or sleep loss. Many personnel will need coaching, mentoring and guidance for them to
adapt and achieve. For the benefit of staff retention, a number of initiatives and forums will
be required to keep people on board. A culture of well-being and human values in action, and
the conflicts associated with modern day business practices and schedules should be

3
Published by ARROW@TU Dublin, 2020

3

Level 3, Vol. 15, Iss. 2 [2020], Art. 19
Level3

December 2020

Technological University Dublin

reconciled and harmonised as much as possible. Training of people managers in soft-skills is
key, and more imaginative and effective staff performance appraisal are required.

8. Work to the project schedule
The quality of the schedule output is wholly dependent on the quality of the inputs when
generating the program. Therefore, knowledgeable and experienced personnel are required
to participate into the scheduling program. Once the schedule is baselined, formal progress
reporting begins. Consolidate the various project trackers for more efficient and centralised control,
and align with the appropriate levels within the schedule hierarchy.

Constant messages, emails and automated reminders relating to timing of deliverables can
substantially distract key personnel from getting the actual work done, as much of their
limited time is being diverted by incessant demands for tedious progress reporting. This is
micro-managing, and this is detrimental to morale. The irony is that little progress is being
made due to the excessive amount of time spent reporting on progress (that is not getting
done in the first place!). Project managers need to carefully balance this, especially where
there is only a very limited number of key personnel per deliverable and/or per project
discipline. Do not exhaust or burden your limited supply of subject matter experts with
excessive reporting demands.

9. Too many meetings
Meetings can take many forms and are a necessary evil, but excessive meetings are a drain
on project finances and schedule. Very soon into a project everyone’s calendar fills up, where
100% of our key personnel’s time can be taken up with meetings. The irony is constant backto-back meetings to progress tasks and activities consume the meagre available time left to
get those done in the first place. Using a meeting forum to micro-manage key deliverables,
rather than trusting key personnel to deliver on their own, is poor use of the limited time and
resources available. Make sure your meetings are productive. Come well prepared with your
meeting agenda. Summarise the main outputs, and agree any follow-ups. Be careful not to
allocate too much work to the too few project personnel whom you mostly rely upon.
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10. Ongoing training in product, process, quality and regulatory
Many people know what to do but not why it is being done. It would be beneficial, therefore,
if each and every contributor on the project had an appropriate understand of the ‘why’. A
suggestion is to have on-going training and communication in basic and more advanced
understanding of your (a) product and (b) process, and also your (c) quality management
system (QMS) and (d) global regulatory affairs. The more your project contributors
understand these four concepts the better it will be for the design, quality, and validation
outputs and deliverables. This will also lead to better traceable decision making, particularly
when using quality risk management, as the impact on product quality and patient safety will
be better understood by all.
11. Practical quality risk management
Embrace all features of quality risk management, and remember that there are more risk assessment
tools available to us than just failure mode and effect analysis (FMEA). The truth be told, many subjectmatter experts avoid volunteering, and being volunteered for, risk management because of the
tedious nature of the classic FMEA spreadsheet approach. Other tools can be more creative, especially
for the risk assessment element. This includes fault tree analysis (FTA), cause and effect diagrams
(Ishikawa diagrams), hazard and operability (HAZOP) analysis, hazard analysis critical control point
(HACCP), and event tree analysis (ETA). The risk review portion of quality risk management program
can also be frequently overlooked. Risk review is critical to monitoring that you are identifying the
appropriate risks and hazards associated with your systems, and that you are indeed taking the right
decisions with respect to subsequent mitigation strategies.

12. Critical quality attributes and process parameters
Have a working list of critical quality attributes (CQAs) available at the earliest opportunity.
Although the quality target product profile (QTPP) may not yet be formally established and
available, ensure the working list of CQAs are traceable to evolving and documented
development studies. Similarly, based on the working list of CQAs, identify associated critical
process parameters (CPPs), define the in-process controls (IPCs), and establish the overall
testing strategy.
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13. Primary gap assessments
As early as practically possible, complete the necessary comparisons between the sending
unit and the receiving unit. Identify the gaps between the facility arrangements, equipment
systems, consumable and disposable components, the raw materials, and the process itself.
Map out the gaps and implement suitable mitigation strategies. Test out the mitigation
strategies before and during the engineering runs, and have everything closed out in time for
subsequent process performance qualification (PPQ) runs.

14. Process risk assessments and control strategy
Based on the proposed manufacturing set-up, conduct a robust process risk assessment, and
establish a suitable process control and microbial control strategy. These take up a lot of time
and energy, and need to be planned and resourced meticulously. Ultimately, we should end
up with all the necessary setpoints, and normal and proven acceptable ranges for critical and
key process parameters, as they relate to critical quality attributes.

15. Supply chain for services and materials
Globally, supply chains are over-stretched for just about every industry, and particularly in
this unprecedented era of the Covid-19 pandemic. Baseline the bill-of-materials (BOM) at the
earliest opportunity. Be careful in your decisions to go with either sole-source or multi-source
suppliers. Have a dedicated team in place to expedite, with appropriate quality oversight,
orders or to source alternative vendors and suppliers.

Do not underestimate how long it can take to get a new supplier or vendor approved and
added to the bid list for both services and materials (can take up to a year and longer). This is
especially true if you intend designing and ordering bespoke single-use disposable
components (plastic/polymeric containers, connectors, assemblies and manifolds) as this list
can run into hundreds of items, and a multitude of supplies and vendors can quickly become
hard to manage due to the numbers involved.

Allow sufficient time to prepare the material specifications, design bespoke single-use
components, conduct audits and qualify suppliers, place purchase orders and agree lead
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times. Allow sufficient time for preparing the warehouse for receipt, quarantining and
subsequent QC release of goods. For each batch prepare an adequate timetable for
dispensing the raw materials, and for assembly of the consumables and disposable
components into a kit for subsequent transfer into the production environment.

When it comes to single use consumables, order in sufficient quantities for engineering
batches. In the earlier engineering batches confirm all single-use consumables, and their
manifold and assemblies, can all be configured and fitted correctly in place. Get any modifications
incorporated into the controlled specifications as soon as possible, and ensure GMP orders for the
updated designs are placed in plenty of time for PPQ runs and subsequent GMP manufacturing.

16. The warehouse is not ready, or is not big enough!
The warehouse is not big enough and will not be ready on time, and whatever you think you
need in terms of space and spare capacity it will not be enough! Single-use consumables can
often be delivered in large boxes with lots of packaging that takes up an inordinate amount
of space. As a contract manufacturing organisation (CMO), you can also expect free-issue of
equipment from clients that will be dedicated to their process and their processes only.
Additional space and strict controls will be necessary to store client dedicated equipment,
otherwise clutter may quickly result if not properly managed.

For a new build, allow for receipt of deliveries earlier than expected, because long lead items
might arrive sooner than expected due to suppliers juggling other customers’ orders and
cancelations. Too early receipt of GMP ordered materials when your warehouse is not
finished or qualified can invalidate the chain of custody of your GMP materials. The worstcase scenario is that you may have to discard the delivery and reorder the goods, and this can
have major implications on cost and schedule. A suggestion is to hire warehouse space from
a third-party to be ready for early deliveries or delays to your new warehouse build. Make
sure you qualify the third-party warehouse provider in advance, and have qualified controls
in place for transportation of goods to your facility.
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17. Computer system validation
Develop efficient and risk-based practices for validating and maintaining your computerised
systems for capable operational and capable performance within the GxP environment. This
is because the majority of software can involve bespoke and/or involves relatively complex
configuration requiring many hours of design, implementation and testing. Most GxP
manufacturing systems and business applications require significant validation investment.
Computer system validation and data integrity assessments therefore need to be carefully
planned and managed, otherwise a disproportionate amount of resources and energy get
diverted constantly to remediate deficiencies. Even after many years of GAMP guidance (good
automated manufacturing practice), computer system validation still presents ongoing
challenges for the industry. Companies need to cease imposing upon themselves excessively
elaborate validation practices. Onerous validation practices can actually detract from the
primary intent of providing evidence that a computerised system is fit for intended, and
instead only result in masses of paperwork that do not necessarily add value or
understanding.

18. Software applications
Carefully consider what software applications are wholly necessary for the business, and
decide who needs what access and level of training. Learning and keeping up to date with
more and more software applications in our place of work can distract our key personnel from
their primary responsibilities and core tasks, especially with constant upgrades associated
with proprietary software. Perhaps the approaching era of artificial intelligence (AI) might just
consider this challenge in the future.

19. Cleaning validation
Cleaning validation can never start too soon. Nowadays, many multi-product contract
manufacturing organisations (CMO) tend towards the use of single-use components, thereby
reducing/eliminating product cross-contamination concerns. It is recommended to formally
document and confirm what components are within scope and what are outside the scope of
cleaning validation. You may potentially only have one or two systems that are multi-use with
multi-product process flow-paths. It does not matter, however, if only one or all equipment
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systems fall within the scope of cleaning validation, a full cleaning validation program needs
to be developed and maintained. This includes cleaning development trials, sampling method
development (swabs and rise samples), sample recovery studies, procedures and protocols
for cleaning validation studies, cleaning validation master plan, project specific cleaning
validation plans, carryover calculations, and rational for setting cleaning and microbial limits.

20. Leveraging the engineering runs for process validation studies
Rather than leaving process validation supporting studies to the PPQ phase, try instead to get
them started during engineering trials, at least in the later batches of the engineering batch
campaign. Agreement would be required by QA, based on an output from quality risk
management, and could include mixing and hold-time studies for example. For this It would
be best to utilise QC released materials and consumables. Although the environment might
still be undergoing qualification in parallel with engineering batches, the use of closed
equipment systems and application of quality risk management may mitigate risks and allow
us to proceed with process validation studies upon receiving QA approval. Consider executing
cleaning validation after each engineering batches also, rather than waiting for the PPQ
phase. Liaise with the production director to determine worst-case operational hold-time
values (for holding buffers and media, in-process materials, and also for dirty and clean holdtime studies) and, if possible, try an validate beyond those maximum predicted timepoints
beginning with the engineering runs.

21. Reprocessing
Reprocessing studies can always be challenging. Know in advance the extent of allowable
reprocessing steps and confirm these first at small scale. Decide what commercial scale
reprocessing steps are feasible and schedule such additional runs during or after the
engineering and PPQ runs. Design and schedule suitable stability and comparability studies
for any reprocessed batches. It is probably a good idea to discuss this with the regulatory
authorities in advance, if practical.
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22. Change control and CAPA
As early as possible in the project, put in place approved processes, procedures and
hierarchies for change control and corrective and preventive actions (CAPA) programs.
Changes to approved documents occur very early in the design phase, and practical and
traceable controls are necessary to manage evolving designs, specifications and procedures.
Consider also putting in place, as soon as possible, robust procedures for deviation handling
and root cause analysis.

23. Sampling Plan
The quality control (QC) department will invariably require the sampling plan much sooner
than you anticipate, for both routine manufacturing and for the non-routine engineering, PPQ
batches and process validation studies. This is especially true when the QC team are involved
with configuring a laboratory information management system (LIMS) application in
accordance with a parallel project schedule.

24. E&L Assessment and GMO licence
It is never too early to commence extractable and leachable (E&L) assessments. Start once all
single-use polymeric consumables have been selected and the purchase orders placed with
the vendors and suppliers. Depending on the extent of the vendor documentation and the
risk categories, the sooner we know in advance the better what, if any, specific extraction
studies will be required and under what exaggerated process conditions they are to be
conducted under. The assessment data will then require review by a trained toxicologist, who
will then make any recommendations regarding the requirements for specific leachable
studies. Similarly, it is never too early to apply for your genetically modified organisms (GMOs)
licence. Robustly prepare, as soon as practically possible, the facility and the QMS for the
audit inspection by local the health and safety authorities. Any delay in the GMO licence being
issued will delay the start of the engineering batches, and put on hold any small-scale studies
where it is required to culture cells
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Figure-1: Visualisation of the many interrelationships amongst key tasks and activities for a typical biopharmaceutical drug substance technology transfer
project. Text boxes with dark-green shading represents end-user responsibilities, unshaded text boxes represent contractor/service-provider
responsibilities, and light green text boxes are potential shared activities.
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